FDA Removes Partial Clinical Hold on TakeAim Leukemia Study, RP2D Established at 300 mg BID

Curis, Inc., a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor (IRAK4, FLT3 and CLK) for the treatment of hematologic malignancies, announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the TakeAim Leukemia Phase 1/2 study of emavusertib. The recommended phase 2 dose (RP2D) f..